Home › Head and Neck Squamous Cell Carcinoma › NCT06606028

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

Tumor-informed ctDNA Testing for Minimal Residual Disease Monitoring Following Curative-intent Treatment of Squamous Cell Carcinoma of the Head and Neck.

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Participants must have histologically or cytologically confirmed squamous cell carcinoma of the head and neck mucosa and skin.
2. Participants must be age \>=18 years.
3. Participants must be planning to receive curative-intent surgery or radiation-based treatment as part of standard of care treatment.
4. Participants must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1\. Contraindication to phlebotomy for removal of 20 mL of peripheral blood each time point (up to 300 mL total over 15 time points).

About the study

This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinomas (HNC) of the head and neck mucosa and skin after curative-intent primary radiation or surgery.

What is being tested

• Blood Specimen Collection (procedure)
• Tumor Tissue Collection (procedure)
• Medical Record Review (other)

Sponsor: University of California, San Francisco · Participants: 250 · Started: Oct 9, 2024

Contact the study team

• Sonia Contreras Martinez · Phone: 415-514-6427

Official record on ClinicalTrials.gov — NCT06606028

Locations in the U.S.

Conditions

• Head and Neck Squamous Cell Carcinoma
• Head and Neck Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.